ImmuPharma PLC - specialist drug discovery and development company - Says its US partner for Lupuzor, Avion Pharmaceuticals LLC, has received a written response from the US Food & Drug Administration that provided detailed guidance on the next steps for the drug’s clinical programme. This included advice on the dosing regime, as well as guidance on the study protocol that can be amended to improve the regulatory outcome.

Lupuzor is a potential treatment for lupus, a condition that affects the immune system and can cause problems with skin, joints, kidneys and other organs.

Current stock price: 4.60 pence, down 31% on Wednesday

12-month change: down 40%

Copyright 2022 Alliance News Limited. All Rights Reserved.